Tick Test & Prophylaxis Proof.
Completed
- Conditions
- yme disease (Lyme ziekte)tick bite (tekenbeet)prophylaxis (profylaxe)antibiotics (antibiotica)
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 2500
Inclusion Criteria
1. 8 yrs and older;
2. Not pregnant;
Exclusion Criteria
1. Not able to give informed consent or do not have a thorough command of the Dutch language;
2. Report other tick bites in the three months before inclusion;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of prophylaxis, i.e. the relative risk (RR) reduction for developing Lyme disease after a tick bite and the Number Needed to Treat (NNT) to prevent one case of Lyme disease. The tick screening results will be used to assess the reduction in NNT when only prescribing prophylaxis if the tick is infected and the engorgement or<br>attachment time are above a certain threshold.
- Secondary Outcome Measures
Name Time Method The number of participants that develop Adverse Events in the month after taking the prophylaxis. <br>Scores for epidemiological risk factors for acquiring tick bites and developing Lyme disease such as exposure to ticks in daily life, participants’ activities when acquiring the tick bite, area of acquiring the tick bite, prevention of tick bites. <br>Differences in NNT for children and adults.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antibiotic prophylaxis efficacy in NL-OMON27133 for Borrelia burgdorferi prevention?
How does the prophylactic antibiotic regimen in NL-OMON27133 compare to standard-of-care treatments for tick-borne Lyme disease?
Which biomarkers correlate with successful prophylaxis outcomes in NL-OMON27133's tick bite intervention?
What are the potential adverse events of long-term antibiotic prophylaxis in NL-OMON27133 and strategies for mitigation?
What alternative prophylactic compounds or combination therapies are being explored alongside RIVM's NL-OMON27133 trial for tick-borne disease prevention?